AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 163 filers reported holding AGIOS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $134 | -12.4% | 5,395 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $153 | +15.0% | 5,395 | -6.5% | 0.00% | 0.0% |
| Q1 2023 | $133 | -32.8% | 5,769 | -18.3% | 0.00% | -50.0% |
| Q4 2022 | $198 | -99.9% | 7,060 | +1.4% | 0.00% | 0.0% |
| Q3 2022 | $197,000 | +28.8% | 6,963 | +1.0% | 0.00% | +100.0% |
| Q2 2022 | $153,000 | -19.9% | 6,895 | +5.2% | 0.00% | 0.0% |
| Q1 2022 | $191,000 | -60.2% | 6,556 | -55.1% | 0.00% | -50.0% |
| Q4 2021 | $480,000 | +34.8% | 14,588 | +89.0% | 0.00% | -33.3% |
| Q3 2021 | $356,000 | -25.4% | 7,718 | -10.8% | 0.00% | -25.0% |
| Q2 2021 | $477,000 | +22.3% | 8,652 | +14.7% | 0.00% | -73.3% |
| Q1 2021 | $390,000 | +11.1% | 7,545 | -6.9% | 0.02% | +15.4% |
| Q4 2020 | $351,000 | +23.6% | 8,103 | -0.0% | 0.01% | +8.3% |
| Q3 2020 | $284,000 | -34.6% | 8,107 | -0.2% | 0.01% | -40.0% |
| Q2 2020 | $434,000 | -7.9% | 8,120 | -38.8% | 0.02% | +66.7% |
| Q1 2020 | $471,000 | -26.6% | 13,267 | -1.3% | 0.01% | 0.0% |
| Q4 2019 | $642,000 | +87.2% | 13,446 | +27.0% | 0.01% | +71.4% |
| Q3 2019 | $343,000 | -34.3% | 10,585 | +1.1% | 0.01% | -41.7% |
| Q2 2019 | $522,000 | -32.2% | 10,472 | -8.3% | 0.01% | -36.8% |
| Q1 2019 | $770,000 | +48.6% | 11,414 | +1.6% | 0.02% | +26.7% |
| Q4 2018 | $518,000 | -5.6% | 11,229 | +57.8% | 0.02% | +7.1% |
| Q3 2018 | $549,000 | -44.2% | 7,117 | -39.0% | 0.01% | -41.7% |
| Q2 2018 | $983,000 | +14.8% | 11,667 | +11.4% | 0.02% | +4.3% |
| Q1 2018 | $856,000 | +80.6% | 10,473 | +26.4% | 0.02% | +76.9% |
| Q4 2017 | $474,000 | -9.2% | 8,287 | +5.9% | 0.01% | -18.8% |
| Q3 2017 | $522,000 | +46.2% | 7,827 | +12.9% | 0.02% | +33.3% |
| Q2 2017 | $357,000 | +35.2% | 6,930 | +53.2% | 0.01% | -7.7% |
| Q1 2017 | $264,000 | +14.3% | 4,523 | -18.1% | 0.01% | +30.0% |
| Q4 2016 | $231,000 | -8.0% | 5,525 | +16.2% | 0.01% | -33.3% |
| Q3 2016 | $251,000 | +17.8% | 4,753 | +57.3% | 0.02% | -31.8% |
| Q3 2015 | $213,000 | -35.6% | 3,021 | +1.5% | 0.02% | -33.3% |
| Q2 2015 | $331,000 | – | 2,977 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Ventures 2007 General Partner LLC | 1,930,369 | $118,428,000 | 83.56% |
| Third Rock Ventures, LLC | 3,070,090 | $188,350,000 | 21.97% |
| Opaleye Management Inc. | 113,500 | $6,963,225,000 | 5.43% |
| BB BIOTECH AG | 1,890,521 | $115,983,000 | 4.72% |
| Eventide Asset Management | 431,600 | $26,479,000 | 3.70% |
| Atika Capital Management LLC | 54,000 | $3,313,000 | 2.55% |
| Cormorant Asset Management, LP | 100,000 | $6,135,000 | 1.26% |
| BRIDGER MANAGEMENT, LLC | 220,099 | $13,503,000 | 0.92% |
| Ghost Tree Capital, LLC | 20,000 | $1,227,000 | 0.67% |
| HAMILTON LANE ADVISORS LLC | 27,544 | $1,690,000 | 0.55% |